Triple-negative breast cancer ( TNBC ) is a subtype of breast cancer,and it is characterized by an aggressive clinical course with a poor prognosis.Treatment for TNBC has attracted much attention in recent years,however,there is no standard treatment for TNBC in clinical setting.The pCR rates of neoadjuvant chemotherapy in TNBC ranges from 12％ to 48％ in the current published data,and it is higher than that in other types of breast cancer,however,the fluctuating range of the TNBC ’s pCR is large in literature.Although the administration of adjuvant chemotherapy for early TNBC is controversial,the regimen without anthracyclines is reported to be suitable for early TNBC patients.Standard cytotoxic agents including taxanes and anthracyclines are still the main choices for TNBC salvage treatment,and the combination with gemcitabine or capecitabine may improve the overall survival.Poly (ADP-ribose) polymerase (PARP) is a new molecular target for TNBC in ongoing studies.Further research on the target-inhibitors such as BSI-201and Olaparib will provide more effective choices to clinical treatment.

Recent studies suggest that astrocyte elevated gene 1 ( AEG-1 ) is almost highly expressed in all types of malignant solid tumors and correlates with poor prognosis,which becomes a prognostic marker for many kinds of tumors.As a strongly basic protein,AEG-1 possesses a transmembrane domain and multiplenuclear localization signals.It is present in the cell membrane,cytoplasm and nucleus.As an oncogene,AEG-1 palys an important role in a virety of malignant biological behaviors of cancer,which range from cell proliferation,apoptosis,migration,adhesion,invasion to tumor angiogenesis and chemotherapy resistance.Its critical role in tumor genesis and progression has made it a potential therapeutic target.

Cytokine-induced killer(CIK)cells are characterized by rapid proliferation, high and broad anti-tumor activities and mild toxicities. Some clinical trials demonstrate that the infusion of a large amount of CIK cells enhances the auto-immune of function in patient, which might help to clean up the remaining tumor cells and minor metastatic tumors and delay the recurrence of tumor with improved curative effects.

Skin toxicities are the most common adverse effects of epidermal growth factor receptor inhibitors(EGFRI).It can result in significant physical and psyehological discomfort,and even leads to interruption or dose modification,and consequently affect the curative effect. Nowadays this adverse effect has attracted lot of attention.It is proposed that clinical management and treatment measures for skin toxicities should be further studied to improve the patients life quality,and guarantee the continuity and best curative effect of the treatment.But more researches on the pathogenesis and its prognostic significance are still expected.

In recent years,tumor immunotherapy has attracted more attention because of its remarkable curative effect in patients with advanced cancer,but often accompanied by immune related adverse events.Understanding the immune related adverse reaction rate,possible mechanism and adverse reaction evaluation criteria and treatment principle of the immune checkpoint inhibitors such as Ipilimumab,Nivolumab and Pembrolizumab,has important significance for the treatment of malignant tumor.

Objective To elevate the efficacy and complications of partial splenic embolization(PSE) using the alginate microglobe(AMG) as embolic material for hypersplenism in cirrhosis.Methods 42 patients with hypersplenism and cirrhosis were treated by PSE,AMG of 250～450 ?m were injected into the arteries of inferior splenic pole,the embolization degree was ranging from 40% to 70%.Results 42 times of embolization were performed in 42 patients,after operation, 35 patients had fever and lasted for 3~15 d,38 patients had abdominal pain,of them, 27 patients needed treatment with analgesic.Treatable a little hydrothorax appeared in 6 ,and no serious complication occurred.WBC and PLT counts were increased 24 hour later(P

NDUFS3 is an essential subunit of mitochondrial NADH:ubiquinone oxidoreductase (complex Ⅰ ) and plays a critical role in the mitochondrial typeⅠ respiration chain.Mutations in this gene are shown to cause neurodegenerative disease such as Leigh syndrome (subacute necrotizing encephalopathy).In recent years,many evidences show that the expression of NDUFS3 proteins are lower in many cancerous cells compared to the corresponding normal cells.It comes to the conclusion that NDUFS3 may play a role in the tumorigenesis.

Sarcopenia is one of common clinical symptom in patients with cancer,which can be regarded as a poor prognosis independent risk factors of disease and death.The main measurements of sarcopenia are magnetic resonance imaging,computerized tomography and positron emission tomography.Sarcopenia is frequently associated with cachexia,and have an influence on the anti-tumor therapeutic influence with each other.In recent years,a mass of clinical research on the application of exercise,nutrition support and drugs,and other comprehensive intervention in patients with sarcopenia emerging constantly,and much achieved good results.The clinical value of sarcopenia in cancer therapy can not be ignored,which should be given more attention.Its mechanism is complex,and intervention means become more various,but more evidence of efficacy and safety is still needed.

Objective To provide basis for treatment and prognosis judgement in order to further normalize diagnosis on non-small-cell lung cancer.Methods The diagnostic results of 146 cases with non-small-cell lung cancer were collected and analyzed.The patients received treatment in our department from Feb.2002 to Aug.2005.Results There were 123 cases of complete pathologic diagnosis,accounting for 84.2% of the total results;among other things there were 42 cases(28.8%)that obtained pathologic diagnosis through operation.There were respectively 31 cases(21.2%),18 cases(12.3%),15 cases(10.3%)and 11 cases(7.5%)that obtained diagnosis through phlegmy cytological examination,lymph node needle biopsy,hydrothorax cytology and bronchoscope among 104 cases without operation.There were 23 cases accounting for 15.7% through clinical diagnosis(on the basis of clinical physical sign and video examination without definite pathologic diagnosis).Conclusion To form a definite pathological diagnosis on tumors before treatment makes treatment be exact and helps to judge tumor development and prognosis.

Prolactin-inducible protein(PIP)is regarded as a kind of specific tumor marker,and detecting the expression of PIP from breast cancer tissues,metastatic lymph nodes and peripheral blood can find breast cancer micro-metastasis effectively.Some technologies such as immunohistochemistry,reverse transcription polymerase chain reaction and so on can detect PIP sensitivily.Recently,these technologies have been used in some clinical and basic studies.Detection rate of breast cancer micro-metastasis is improved effectively when PIP is combined with other tumor makers,especially mammag-lobin and cytokeratin 19.